Genetic Testing Market Regional Analysis

Genetic Testing Market size was valued at USD 7.42 Billion in 2023 and is poised to grow from USD 9.05 Billion in 2024 to USD 44.41 Billion by 2032, growing at a CAGR of 22% during the forecast period (2025-2032).

Genetic Testing Market providers need to focus on maximizing their business scope by reaching into new markets and developing Genetic Testing for different industrial and personal uses. Raising new capital to fund their R&D and business expansion efforts will be essential for new genetic testing companies going forward. The development of custom robots for specific applications across different industry verticals will also help companies expand their sales potential in the future.  'Genentech Inc. (U.S.)', 'Sorenson Genomics, LLC (U.S.)', 'Abbott Molecular (U.S.)', 'Bayer Diagnostics (U.S.)', 'Genomic Health (U.S.)', 'HTG Molecular Diagnostics (U.S.)', 'Centogene N.V.(Germany)', 'Burning Rock Biotech Limited (China)', 'Illumina, Inc. (U.S.)', 'Thermo Fisher Scientific, Inc. (U.S.)', 'Quest Diagnostics Incorporated (U.S.)', 'Foundation Medicine, Inc. (U.S.) ', 'PerkinElmer, Inc. (U.S.)', 'Myriad Genetics, Inc. (U.S.)', 'Laboratory Corporation of America Holdings (U.S.)', 'Biocartis (U.S.)', 'BioHelix (Taiwan )', 'Celera Genomics', 'PacBio (U.S.)', 'Luminex Corporation (U.S.)', 'Danaher Corporation (U.S.)'

Rising Awareness and Demand for Personalized Medicine

Genetic Testing beyond DNA: Today, genetic testing is not just associated with examining DNA but goes beyond that. Genetic testing is expanding to comprise RNA and epigenetic alterations that do not change the DNA ‘code’, but impact how the code is understood and applied within human cells. This will not only improve genetic variation detection but also help understand these variants and their importance for an individual’s health.

Geographically, North America is dominating the genetic testing market owing to various reasons including economic, technological and societal factors. The leading nations in the region like Canada, the United States, brag about well-established healthcare infrastructure with modernized facilities, clinical laboratories, and research institutes. This infrastructure aids the broader use and innovations in genetic testing techniques. This, along with innovations in the region, is driving the growth of the market. The leading companies in North America include 23andMe, Illumina Inc., Blueprint Genetics Oy, Quest Diagnostics, Myriad Genetics, and more.